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AbstrAct
Background Medicines optimisation is a key role for 
hospital pharmacists, but with ever-increasing demands 
on services, there is a need to increase efficiency while 
maintaining patient safety.
Objective To develop a prediction tool, the Medicines 
Optimisation Assessment Tool (MOAT), to target patients 
most in need of pharmacists’ input in hospital.
Methods Patients from adult medical wards at two 
UK hospitals were prospectively included into this 
cohort study. Data on medication-related problems 
(MRPs) were collected by pharmacists at the study 
sites as part of their routine daily clinical assessments. 
Data on potential risk factors, such as number of 
comorbidities and use of ’high-risk’ medicines, were 
collected retrospectively. Multivariable logistic regression 
modelling was used to determine the relationship 
between risk factors and the study outcome: preventable 
MRPs that were at least moderate in severity. The model 
was internally validated and a simplified electronic 
scoring system developed.
Results Among 1503 eligible admissions, 610 
(40.6%) experienced the study outcome. Eighteen risk 
factors were preselected for MOAT development, with 
11 variables retained in the final model. The MOAT 
demonstrated fair predictive performance (concordance 
index 0.66) and good calibration. Two clinically relevant 
decision thresholds (ie, the minimum predicted risk 
probabilities to justify pharmacists’ input) were selected, 
with sensitivities of 90% and 66% (specificity 30% and 
61%); these equate to positive predictive values of 47% 
and 54%, respectively. Decision curve analysis suggests 
that the MOAT has potential value in clinical practice in 
guiding decision-making.
Conclusion The MOAT has potential to predict those 
patients most at risk of moderate or severe preventable 
MRPs, experienced by 41% of admissions. External 
validation is now required to establish predictive accuracy 
in a new group of patients.
IntroductIon
Medicines are the most common inter-
vention in healthcare.1 However, there 
is growing evidence of a need to improve 
medicines use.1–7 Medication safety 
is high on international and national 
agendas, with recent publication of the 
WHO’s third Global Patient Safety Chal-
lenge: Medication Without Harm,7 and 
a recent report on the prevalence and 
economic burden of medication errors 
in the English National Health Service.8 
While the majority of medicine use occurs 
in primary care, safe use of medicines 
in secondary care and at transitions of 
care continue to be areas of concern,7 8 
together with ongoing calls for hospital 
pharmacy services to operate more effi-
ciently.9–14
Clinical prioritisation has been 
proposed as a way to permit pharmacy 
services to focus on those in greatest need 
and where clinical pharmacy input is 
likely to have greatest impact, requiring a 
method to triage patients to assign ‘phar-
maceutical acuity’.14 15 Prediction tools 
to identify hospitalised patients at risk 
of adverse medication-related outcomes 
have previously been developed,16–27 but 
the majority identify patients at risk of 
adverse drug reactions,17–19 adverse drug 
events20 21 or medication errors22 in isola-
tion and/or are based on ‘expert opinion’ 
rather than statistical determination.23–27
This study therefore aimed to develop 
a methodologically sound prognostic 
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model,28–31 the Medicines Optimisation Assessment 
Tool (MOAT), to identify hospital patients most 
in need of pharmacists’ input based on their risk of 
moderate or severe preventable medication-related 
problems (MRPs). Our objectives were to develop 
a decision aid for use in clinical practice to allocate 
patients to risk groups and to assess its predictive 
performance and clinical usefulness.
Method And AnAlysIs
study design
The MOAT was developed using a prospective cohort 
study involving adults admitted to the medical wards 
of two hospitals in South East England, described in 
detail in a published protocol.32 Eligible patients were 
consecutively included at Hospital A from 28 April 
2016 to 31 May 2016 and Hospital B from 19 October 
2016 to 1 November 2016. As previously described,32 
patients admitted for investigation only (ie, elective 
admissions), and those not prescribed medication 
during the admission, were excluded on the basis that 
they did not represent the target population for the 
MOAT. Patients were also excluded if their prescribing 
records were not reviewed by a clinical pharmacist 
during their admission, as it was not possible to ascer-
tain whether they experienced an MRP. In addition to 
these previously published exclusion criteria, patients 
were also excluded if their prescribing records and/
or medical notes were unavailable; this was to ensure 
completeness of medicine-related predictor data. MRP 
data were collected for all study patients from admis-
sion to discharge from hospital or the date the study 
closed (2 weeks after inclusion of the final patient), 
whichever occurred sooner.
Descriptions of the outcome for the prognostic 
modelling, preselected candidate predictors and 
methods of data collection are described in detail 
elsewhere.32 In summary, the outcome event was the 
occurrence of at least one moderate or severe prevent-
able MRP, chosen on the basis that prioritisation 
would be required for patients at risk of moderate or 
severe MRPs irrespective of the number. MRPs were 
defined as ‘all circumstances involving a patient’s drug 
treatment that actually, or potentially, interfere with 
the achievement of an optimal outcome’.33 Severity 
was assessed by an expert panel comprising the prin-
cipal investigator, a hospital pharmacist, a senior 
nurse and a consultant physician using a validated 
visual analogue scale.34 Preventability was assessed 
at the point of identification and expressed as a 
dichotomous variable of yes or no. Further informa-
tion on study outcomes, including illustrative exam-
ples, is given in online supplementary appendix S1. 
We focused on moderate or severe MRPs as these 
are most clinically relevant. Similarly, we focused on 
preventable MRPs to ensure the MOAT identifies 
patients with MRPs amenable to pharmacist interven-
tion. Eighteen candidate predictors were preselected 
(online supplementary appendix S1): age, socio-
economic status, previous allergy, body mass index, 
number of previous hospital admissions, primary diag-
nosis, number of comorbidities, history of dementia, 
number of medicines prescribed, use of one or more 
of a list of ‘high-risk medicines’, parenteral medicine 
administration, renal function, liver disease, serum 
albumin, serum potassium, serum sodium, white cell 
count and platelet count. The following changes were 
made to the proposed candidate predictors following 
publication of the protocol:32
 ► an organ-based approach35 was used to categorise 
primary diagnosis rather than the proposed Interna-
tional Classification of Diseases system. This was to 
reduce the risk of misclassification given that a defini-
tive diagnosis may not be known at the point of hospital 
admission. This resulted in eight categories: cardiovas-
cular, respiratory, gastrointestinal, genitourinary, muscu-
loskeletal-integumentary, endocrine-metabolic, nervous 
system/mental disorders and ‘other’ (all other diagnoses 
combined);
 ► the high-risk medicine category ‘antibiotics’ was 
changed to ‘antimicrobial agents’ to include antivi-
rals, antifungals and antiprotozoal agents as well as 
antibiotics;
 ► renal function was estimated using the modified Modi-
fication of Diet in Renal Disease equation rather than 
the Cockcroft-Gault equation.36 This was due to limited 
availability of patient weight data.
Data entry checks for the accuracy of candi-
date predictor data were performed on a randomly 
selected 10% sample of patients. Sixteen data items 
were checked for each of these patients, and accuracy 
calculated as the percentage of data items recorded 
correctly. We also developed and used a ‘MRP identi-
fication assessment exercise’ to quantify potential vari-
ability in MRP identification between pharmacists at 
the study sites. This involved the use of four fictitious 
medication charts each including three or four MRPs. 
Each MRP was considered to have a binary outcome 
in terms of whether or not it was identified by each 
pharmacist. The percentage agreement between phar-
macists was calculated and Randolph’s kappa used to 
assess chance-adjusted agreement (online supplemen-
tary appendix S1).
The sample size was dictated by practical consid-
erations, permitting inclusion of 1500 patients plus 
10% to allow for patient exclusions.32 Adequacy 
was assessed using the ‘events per variable’ (EPV)37 
and precision methods, based on a conservative esti-
mate for the outcome prevalence of 32%, obtained 
following pilot work with 200 patients. This gave an 
anticipated EPV of 13, exceeding the ‘rule of thumb’ 
of 10 or more EPV,37 and the ability to estimate the 
MOAT’s sensitivity with 95% CI of ±3%, which we 
considered an acceptable level of precision in terms of 
clinical usefulness.
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data analysis
Data analysis was performed as specified in the 
protocol to reduce the risk of data-driven model devel-
opment.32 All continuous predictors were analysed as 
such; we did not use categorisation as this is associ-
ated with reduced model reliability and overoptimistic 
predictive performance.31 Predictors with a wide 
range in units were analysed as deciles to aid compar-
ison of predictive effects among variables (age, esti-
mated glomerular filtration rate, platelet count and 
the percentage deprivation rank used as a measure 
of socioeconomic status); changes in predictive effect 
per unit increase would otherwise be small, making 
comparison with other predictors more difficult.38 
Missing candidate predictor data were handled using 
multiple imputation and truncation used to reduce the 
influence of outliers on the regression coefficients;38 
truncation was chosen instead of data transformation 
due to the potential impact of transformations on 
interpretability of the MOAT.39 Further information 
on missing data and truncation are given in Online 
supplementary appendix S1. Linearity of continuous 
predictors was checked using multivariable fractional 
polynomial modelling;40 41 this failed to reject linear 
relationships for the continuous predictors, and data 
transformations were therefore not required. There 
was also no evidence of multicollinearity (assessed 
by calculating variance inflation factors).38 Explora-
tory investigations into possible interactions between 
predictors were not performed as none were hypoth-
esised a priori, while interactions may have been 
present, thorough assessment of possible interactions 
during modelling increases the risk of overfitting and 
does not necessarily increase prognostic model perfor-
mance.38 42 43
Model development is described in online supple-
mentary appendix S1. In summary, a random effects 
model was used to account for possible correlation 
between patients admitted more than once during the 
study period.44 Backwards elimination was used to 
reduce the set of candidate predictors during model-
ling as our aim was to produce a parsimonious model, 
thereby increasing clinical applicability while retaining 
reasonable predictive performance.38
Internal validation involved the use of 200 bootstrap 
samples (online supplementary appendix S1).38 42 45 
This involved drawing random samples from the devel-
opmental dataset and constructing a model, similar to 
the original regression model, in each random sample. 
Each bootstrap model was then applied to the orig-
inal developmental dataset, and optimism calculated 
as the average difference in performance, in terms of 
the concordance index (c-index) and calibration slope, 
between the bootstrap and developmental datasets. 
Bootstrap validation suggested slight overfitting, the 
model was therefore adjusted for optimism by multi-
plying each of the model’s regression coefficients by a 
‘linear shrinkage factor’; the adjusted model was then 
used to create an electronic scoring system. Our orig-
inal proposal was to develop a simplified scoring system 
by converting the regression coefficients from the 
final prognostic model into scores,46 but an electronic 
system permitted use of the full regression equation, 
so preventing loss of predictive accuracy, simplifying 
use and reducing the risk of calculation errors. It also 
permitted incorporation of usage instructions.
While prognostic models provide estimates of the 
probability that an individual patient will experience 
an outcome event, this does not provide guidance 
on an appropriate course of action. ‘Risk groups’ 
are therefore often created, which indicate a specific 
course of action, creating a ‘decision aid’ or ‘clinical 
decision rule’.38 We created three risk groups, cate-
gorising patients as low, medium or high risk. The 
choice of decision thresholds, which are the cut-offs 
for predicted risk probabilities to justify an interven-
tion (in this case, pharmacists’ input), was guided by 
a survey of healthcare professionals and patient/public 
representatives, and consensus views of practising 
pharmacy staff. This is described further in online 
supplementary appendix S1. As concern exists over 
the arbitrary nature of categorisation, with all patients 
within a group being assumed to have the same risk,42 
we chose to report both the risk group and individual 
predicted risk probability for each patient assessed 
using the MOAT. This was to guide general priori-
tisation decisions (by categorising patients as high, 
medium or low-risk) and also to permit some degree 
of prioritisation within each category if required.
Assessment of clinical usefulness and credibility
Clinical usefulness was assessed using decision curve 
analysis,38 47 which assesses model performance over a 
range of decision thresholds using the theoretical rela-
tionship between threshold probabilities and the rela-
tive value of false positive and false negative results,48 
calculated as the net benefit (online supplementary 
appendix S1). By varying the threshold probability, it 
is possible to produce a ‘decision curve’ (a plot of net 
benefit against threshold probability), which informs 
the range of threshold probabilities for which the 
prediction model would be of value in clinical prac-
tice.49
Adoption of a prediction tool into clinical practice 
requires clinical credibility,50 which is based on factors 
such as content validity, ease of use, acceptability of the 
time taken to use the tool and acceptability of the false 
negative rate.51 52 To investigate these we used: (1) a 
consensus method to harness the insights of pharmacy 
professionals regarding the perceived clinical credi-
bility and usability of the MOAT; (2) an assessment 
of the workload implications and (3) an assessment of 
the clinical implications of false negative predictions 
(described in online supplementary appendix S1).
Results are reported according to the Transparent 
Reporting of a multivariable prediction model 
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Figure 1 Participant flow diagram. MRP, medication-related problems.
for Individual Prognosis Or Diagnosis (TRIPOD) 
reporting guidelines for prognostic model studies,30 
and Strengthening the Reporting of Observational 
Studies in Epidemiology reporting guidelines for 
observational studies.53 All analyses were conducted 
using Stata V.14.2.
results
overview of included patients
In total, 1652 patient admissions were included in the 
study: 1100 from Hospital A and 552 from Hospital 
B (figure 1). Of these admissions, 149 (9%) were 
excluded: 114 did not meet the eligibility criteria, 
and prescribing records and/or medical records were 
unavailable for 35. Online supplementary appendix S2 
provides further information of this and other online 
supplementary results. Of the remaining 1503 admis-
sions, 1378 (92%) were followed up until discharge 
from hospital: 933 (93%) of 1006 at Hospital A and 
445 (90%) of 497 at Hospital B. The remaining 125 
admissions were followed until the study end date (2 
weeks after inclusion of the final patient at each site). 
Fifty-seven patients entered the study twice: 46 at 
Hospital A and 11 at Hospital B. One further patient 
at Hospital B entered the study three times. The total 
number of unique patients included in the study was 
therefore 1444 (960 at Hospital A and 484 at Hospital 
B). Of the 1503 admissions, 894 (59.5%) experienced 
at least one MRP, with 610 (40.6%) experiencing the 
outcome event, namely at least one moderate or severe 
preventable MRP.
Key characteristics of the 1503 study admissions are 
summarised in table 1.
Data entry checks were performed for 152 admis-
sions (99 from Hospital A and 53 from Hospital B), 
giving a total of 2432 data item checks; 2429 (99.9%) 
were correctly recorded, with remedial action taken to 
refine data entry where necessary.
MrP identification assessment exercise
The overall percentage agreement (proportion of 
MRPs identified) by 59 pharmacists from the study 
sites was 84.5%, with a Randolph’s kappa coefficient 
of 0.50 suggesting ‘moderate agreement’.54 55 Further 
details are given in online supplementary appendix S2.
exploratory data analysis
A review of the distributions of the preselected cate-
gorical predictors identified five categories each repre-
senting fewer than 5% of the study population: theo-
phylline and aminophylline, immunosuppressants, 
cytotoxics, lithium and ‘other high-risk medicines’ 
(table 1). As all were categories of high-risk medicines, 
these categories were combined to create a larger 
‘other high-risk medicines’ category. Clozapine was 
also moved from ‘other high-risk medicines’ to ‘antip-
sychotics’ on the basis that it is more closely related in 
terms of pharmacological use.
Truncation was required to reduce the influence of 
outliers for seven variables, and analysis of missing 
predictor data supported use of multiple imputation 
(see online supplementary appendix S2).
Adequacy of sample size
Following data collection, it was possible to review the 
adequacy of the sample size. Two changes affected the 
EPV calculation: the increased outcome prevalence 
compared with the initial estimate and the reduced 
number of variables. As non-linear transformations 
were not required and no interactions between predic-
tors examined, this resulted in an increase in the EPV 
to 18. The higher number of outcome events also led 
to increased precision in estimation of the MOAT’s 
sensitivity compared with our initial estimate.32
Model building
Thirteen predictors were retained in the model 
following backward elimination: socioeconomic 
status, number of comorbidities, number of medi-
cines, estimated glomerular filtration rate, white cell 
count, previous allergy, systemic aminoglycosides and 
glycopeptides, other systemic antimicrobials, epilepsy 
medicines, antidepressants and three primary diag-
noses (nervous system/mental disorders, respiratory 
and gastrointestinal). After considering the sensibility 
of using these predictors, we excluded socioeconomic 
status due to: (1) its relative complexity, with potential 
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Table 1 Characteristics of study admissions
Characteristic
Admissions=1503
Mean/median /
n (% of 
admissions)
Missing 
values
n (% of 
admissions)
Demographic
Age (years) Median: 75
IQR: 58–85
0
Gender (female) 693 (46.1%) 0
Socioeconomic status, ranked using 
English Indices of Deprivation 2015
– Index of Multiple Deprivation75 *
Median: 50†
IQR: 30–79
6 (0.4%)
Ethnic origin (white) 1208 (85.9%)† 96 (6.4%)
Patient related
Previous allergy 582 (38.8%)† 1 (0.07%)
Body mass index (kg/m2; healthy 
weight range 18.5–24.9)
Median: 24.9†
IQR: 21.4–29.1
341 (22.7%)
Number of hospital admissions in 
previous 6 months
Median: 0
IQR: 0–1
0
Primary diagnosis:
Endocrine and metabolic 82 (5.5%) 0
Nervous system and mental 
disorders
149 (9.9%) 0
Cardiovascular system 315 (21.0%) 0
Respiratory system 332 (22.1%) 0
Gastrointestinal system 144 (9.6%) 0
Genitourinary system 144 (9.6%) 0
Musculoskeletal-integumentary 
systems
93 (6.2%) 0
All other categories 244 (16.2%) 0
Number of comorbidities Median: 4
IQR: 2–5
0
History of dementia 161 (10.7%) 0
Length of hospital stay (days) Median: 5
IQR: 2–12
0
Medicines related
Medicines reconciliation completed 1292 (86.0%) 0
Number of medicines‡ Median: 8
IQR: 5–10
0
Parenteral medicines administration 1008 (67.1%) 0
Use of high-risk medicines:
Systemic antimicrobials 
(excluding aminoglycosides and 
glycopeptides)
937 (62.3%) 0
Antidepressants 351 (23.4%) 0
Anticoagulants 312 (20.8%) 0
Antidiabetic medication 299 (19.9%) 0
Epilepsy medicines 227 (15.1%) 0
Therapeutic heparin 222 (14.8%) 0
Antiarrhythmics 150 (10.0%) 0
Opioids 145 (9.6%) 0
Aminoglycosides and glycopeptides 105 (7.0%) 0
Antipsychotics (excluding 
clozapine)
92 (6.1%) 0
Other high-risk medicines 
(clozapine, antiretrovirals, 
medicines for Parkinson’s disease)
40 (2.7%) 0
Theophylline and aminophylline 38 (2.5%) 0
Continued
Characteristic
Admissions=1503
Mean/median /
n (% of 
admissions)
Missing 
values
n (% of 
admissions)
Immunosuppressants 21 (1.4%) 0
Cytotoxics 14 (0.9%) 0
Lithium 6 (0.4%) 0
Laboratory results
Renal function—estimated 
glomerular filtration rate (mL/
min/1.73 m2; normal >90)§
Median: 73†
IQR: 53–99
9 (0.6%)
Liver disease¶ 164 (10.9%) 0
Serum albumin (g/L; reference 
range 35–50)
Mean: 33.0†
SD: 6.0
26 (1.7%)
Serum potassium (mmol/L; 
reference range 3.5–5.3)
Mean: 4.4†
SD: 0.62
30 (2.0%)
Serum sodium (mmol/L; reference 
range 133–156)
Mean: 137.2†
SD: 5.2
3 (0.2%)
White cell count (109/L; reference 
range 3.2–11.0)
Median: 9.8†
IQR: 7.5–12.8
6 (0.4%)
Platelet count (109/L; reference 
range 120–450)
Median: 244†
IQR: 192–312
8 (0.5%)
*Deprivation rank based on patients’ postcode, shown as the ranked 
position as a percentage of all neighbourhoods in England (where one is 
the most deprived).
†Results for patients without missing data.
‡Number of ‘regular’ medicines prescribed on the first full day of 
admission to hospital (ie, excluding ‘when required’ and ‘once only’ 
medicines, dietary products, non-medicated topical products, wound 
dressings).
§Glomerular filtration rate estimated using modified Modification of Diet 
in Renal Disease equation.36
¶Liver disease defined as alanine aminotransferase/alkaline phosphatase 
and/or bilirubin ≥3 times normal range and/or documented liver disease.
Table 1 Continued
to reduce ease of use of the MOAT in clinical practice; 
(2) recognition that inclusion may reduce the gener-
alisability of the MOAT by restricting use to English 
hospitals; (3) the minimal impact of removal on the 
model’s c-index (0.3% reduction). Once socioeco-
nomic status was excluded from the model, ‘antide-
pressants’ became non-significant and was therefore 
also excluded, leaving 11 predictors in the final model 
(table 2).
The c-index for the unadjusted model was 0.681, 
95% CI 0.654 to 0.708, with good calibration (see 
online supplementary figure S3; calibration slope 
0.974, intercept 0.012). Following bootstrapping, the 
c-index was 0.657; optimism for the calibration slope 
(0.855) was used as a linear shrinkage factor to adjust 
the regression coefficients of the regression model56 
(table 2).
The resulting regression equation can be used to 
calculate predicted risk for an individual patient 
(online supplementary appendix S4).
The sensitivity of the MOAT at the decision threshold 
separating low-risk and medium-risk patients was 
89.9% (95% CI 87.6% to 92.4%), specificity 30.2% 
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Table 2 Multivariable association between predictors and outcome events after correction for optimism, including the model constant
Predictor
Adjusted regression coefficient*†
(95% CI) P value‡
Number of comorbidities 0.125 (0.0663 to 0.184) <0.001
Estimated glomerular filtration rate/10 (ml/min/1.73 m2) −0.0308 (−0.0628 to 0.0012) 0.059
White cell count (109/L) 0.0234 (−0.0007 to 0.0476) 0.057
Number of medicines 0.0347 (0.0063 to 0.0630) 0.016
Previous allergy§ 0.272 (0.0591 to 0.484) 0.012
Nervous system and mental disorders§ 0.354 (0.0156 to 0.693) 0.040
Respiratory system§ −0.234 (−0.493 to 0.0253) 0.077
Gastrointestinal system§ −0.533 (−0.911 to −0.156) 0.006
Aminoglycosides and glycopeptides§ 0.331 (−0.0457 to 0.708) 0.085
Other systemic antimicrobials§ 0.311 (0.0777 to 0.545) 0.009
Epilepsy medicines§ 0.385 (0.0950 to 0.675) 0.009
Constant −1.674
*Relationship between the independent and dependent variable (amount of increase in predicted log odds of the outcome event that would be predicted 
by a one unit increase in the independent variable).
†Original regression coefficients corrected by uniform linear shrinkage factor (0.855).
‡Test for difference between admissions with and without occurrence of outcome event. Obtained from multivariable regression modelling.
§Categorical exposure variable. For the purposes of calculating the predicted risk for individual patients, categorical variables are coded as ‘one’ if present 
and ‘zero’ if absent.
Figure 2 Decision curve for the Medicines Optimisation Assessment Tool.
(95% CI 27.2% to 33.2%) and positive predictive 
value (PPV) 46.8% (95% CI 45.5% to 48.1%). At the 
threshold between medium-risk and high-risk patients, 
the MOAT’s sensitivity was 66.2% (95% CI 62.4% to 
70.0%), specificity 61.0% (95% CI 57.8% to 64.2%) 
and PPV 53.7% (95% CI 51.2% to 56.2%). These 
decision thresholds represent the minimum predicted 
risk probabilities that justify pharmacists’ input. As 
described in online supplementary appendix S1, the 
low/medium threshold was selected to identify 90% 
of patients likely to experience the study outcome; 
the medium/high threshold was informed by work-
load pressures, identifying the patients pharmacists 
should prioritise if they only have capacity to see 
50%; it therefore provides a pragmatic indication of 
the potential clinical usefulness of the MOAT during 
periods of limited staffing.
The decision curve for the MOAT is shown 
in figure 2 and more detailed results in online 
supplementary appendix S2. In summary, between 
threshold probabilities of approximately 15% and 
70%, the MOAT is better than both the ‘treat none’ 
and ‘treat all’ strategies, suggesting it is of value for 
threshold probabilities within this range.48 As both 
the low/medium and medium/high risk thresholds 
fall within this range (25% and 35% predicted risk 
probability, respectively), the MOAT can be consid-
ered to be clinically useful. Should a higher decision 
threshold be selected (due to extreme work pres-
sures), the MOAT would continue to be of value in 
terms of clinical decision-making up to a threshold 
probability of approximately 70%, suggesting signif-
icant flexibility.
The resulting MOAT was developed as a Microsoft 
Excel sheet (figure 3), which calculates the estimated 
glomerular filtration rate, predicted probability of 
experiencing a moderate or severe preventable MRP 
and the patient’s risk category.
Assessment of clinical credibility
The MOAT was perceived as clinically credible and 
usable by practising pharmacy professionals (online 
supplementary appendix S2). Additionally, the work-
load implications, based on the time taken to apply 
the MOAT compared with potential time saved by 
deprioritising low-risk patients, were considered to be 
reasonable. The results also suggest that ‘false negative’ 
patients may experience fewer outcome events that are 
of lower severity, compared with patients categorised 
as medium or high-risk.
 o
n
 8 M
arch 2019 by guest. Protected by copyright.
http://qualitysafety.bmj.com/
BM
J Qual Saf: first published as 10.1136/bmjqs-2018-008335 on 7 March 2019. Downloaded from 
7Geeson C, et al. BMJ Qual Saf 2019;0:1–12. doi:10.1136/bmjqs-2018-008335
Original research
Figure 3 Screenshot of Medicines Optimisation Assessment Tool data entry sheet.
dIscussIon
Key findings
Over 40% of admissions experienced an outcome 
event, namely at least one moderate or severe prevent-
able MRP. The predictive performance of the MOAT 
was fair (c-index 0.66), with a sensitivity of 90% for 
the low/medium risk threshold (specificity 30%, PPV 
47%) and 66% for the medium/high risk threshold 
(specificity 61%, PPV 54%). Decision curve analysis 
suggests that the MOAT has the potential to be clini-
cally useful in guiding decision-making at these clini-
cally relevant decision thresholds.
comparison with previous work
The MRP prevalence found in the present study 
(59.5%) is consistent with previous research. Blix et 
al57 reported a prevalence of 81%; the data collec-
tion method and sample population were similar to 
the present study, but the higher prevalence may be 
explained by differences in MRP categorisation. Two 
more recent studies (both using similar methods to the 
present study), reported MRP prevalence rates of 52% 
and 53%.58 59 No previous estimate for the prevalence 
of moderate or severe preventable MRPs exists, but our 
results are consistent with Blix’s finding that approxi-
mately half of all MRPs experienced by 81% of hospi-
talised patients were ‘extremely important’ or ‘major’ 
in terms of clinical significance.57
Other statistical models to predict adverse medica-
tion-related outcomes in hospitalised patients have 
been developed,16–22 but it is not possible to make 
direct comparisons with the MOAT due to differences 
in the type of outcome predicted and/or their proposed 
target age group, with four models predicting risk in 
adults over 65 years only.17 18 20 21 Of these existing 
models, five are reported to have satisfactory predic-
tive performance (c-index of 0.70–0.78),16–18 21 22 but 
all have methodological shortcomings and limitations 
that may limit their potential reliability and/or applica-
bility, particularly those developed prior to publication 
of the Prognosis Research Strategy (PROGRESS) Part-
nership and TRIPOD recommendations.28–30 Method-
ological shortcomings include: (1) use of inadequate 
EPV, with only two of the five studies using an EPV 
of 10 or more;16 17 (2) poor reporting on quantity 
and handling of missing data (all studies); (3) use of 
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univariable analysis to select predictors for inclusion 
in modelling (all studies); (4) categorisation of predic-
tors during modelling16–18 21 and (5) no adjustment for 
overoptimistic predictions.16–18 21 Regarding poten-
tial limitations in use, risk groups were not created 
for three of the models16 21 22; one requires complex 
categorisation such as calculation of the Charlson 
index;16 and all use unclear predictor definitions. To 
our knowledge, the present study is also the first to 
use decision curve analysis to assess clinical usefulness.
Of five studies that developed prediction tools based 
on expert opinion,23–27 two provide no data on predic-
tive performance.23 26 Of the remaining studies, it is 
difficult to make direct comparisons with the MOAT 
due to limitations such as small sample sizes,27 60 or 
lack of methodological information.25 There are also 
potential limitations related to the usability of existing 
tools, such as inclusion of predictors with subjec-
tive assessments,24 the need for fully integrated elec-
tronic information systems24 25 or complex predictor 
categorisation.27
In summary, we believe that none of the existing 
prediction tools have evidence for sufficient predictive 
accuracy and/or generalisability to recommend them 
for routine use outside of the site where they were 
developed. Although the MOAT’s c-index is slightly 
lower than some of the other prediction models 
reviewed, it has advantages in terms of robust method-
ology, which increases its potential reliability, usability 
and generalisability.
Implications for practice
While it is not possible to advocate routine use of 
the MOAT prior to completion of external valida-
tion,29 the MOAT has potential to be applicable to 
adult hospitalised medical patients (general, acute and 
elderly medicine), irrespective of age. Given the diverse 
characteristics of the sample population (table 1), the 
MOAT also has potential applicability to a wide range 
of patients in terms of age, ethnicity, comorbidities and 
medical conditions. The MOAT was also perceived as 
clinically credible and usable by practising pharmacy 
professionals.
The MOAT has a modest c-index (0.66), but while 
the discriminative ability of a prognostic model is 
important, Steyerberg advises that ‘it is not possible 
to indicate a minimum value for the c-index to make 
a model clinically useful’.38 This is because the c-index 
alone does not consider the consequence of false posi-
tive or false negatives predictions.38 49 Use of deci-
sion thresholds, that is, the minimum predicted risk 
probabilities to justify pharmacists’ input, allowed 
calculation of the MOAT’s classification measures 
(sensitivity, specificity and predictive values). This 
permitted performance to be assessed at clinically 
relevant thresholds as opposed to the entire range of 
model-predicted probabilities.61 In terms of clinical 
utility, our aim was to produce a prediction tool able 
to correctly identify 90% of patients likely to experi-
ence a moderate or severe preventable MRP (ie, 90% 
sensitivity), a level of accuracy deemed appropriate 
by previous researchers62 and confirmed by our own 
research.63 We were able to achieve 90% sensitivity 
at the low/medium risk threshold (equivalent to a 
25% predicted probability that a patient will experi-
ence an outcome event), meaning that only 10% of 
patients experienced the study outcome despite having 
a predicted probability below this threshold; our data 
also suggest these false negative patients experienced 
fewer outcome events that were of lower severity, 
compared with the true positive patients. While spec-
ificity at the low/medium risk threshold was modest 
(30%), the MOAT identified the 22% of patients least 
likely to experience the study outcome. We believe 
that the low/medium risk decision threshold is there-
fore reasonable in terms of the risks and benefits of 
the MOAT. These results also suggest that the MOAT 
has potential to prioritise pharmacists’ input while 
maintaining patient safety, a recognised need for clin-
ical pharmacy services given limited resources and 
increasing demands.64
We were able to further investigate the potential 
clinical usefulness of the MOAT using decision curve 
analysis. Decision curves inform the range of threshold 
probabilities where prediction models would be of 
value in clinical practice, measured as the net benefit 
(a theoretical relationship between threshold probabil-
ities and the relative value of false positive and nega-
tive results).48 As with classification measures, decision 
curves therefore permit assessment of performance at 
clinically relevant thresholds. The MOAT’s decision 
curve suggests net benefit across a significant range of 
threshold probabilities (15%–70%); decision thresh-
olds within this range therefore have potential to be 
useful in clinical practice in guiding decision-making. 
As above, our aim was for 90% sensitivity, which was 
achieved with a decision threshold of 25% predicted 
risk probability (the low/medium risk threshold). This 
threshold, plus the medium/high risk threshold, used 
to indicate clinical usefulness during limited staffing 
(35% predicted risk probability), both fall within 
the range shown to have ‘net benefit’; the MOAT 
can therefore be considered to be clinically useful at 
thresholds that are relevant in practice. Furthermore, 
the creation of risk groups permits pharmacists to 
take account of workload capacity when prioritising 
patients, as does the reporting of both the predicted 
risk probability and risk group for individual patients.
The MOAT may require development of implemen-
tation strategies regarding the level of pharmacy input 
required by patients dependent on their risk categorisa-
tion. This might range from either no intervention for 
low-risk patients or one short face-to-face discussion 
following admission, to more intensive interventions 
for patients in higher risk categories (such as medicines 
reconciliation and medication review). It may also be 
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possible to combine the MOAT with other triggers for 
pharmacy review, for example, swallowing difficul-
ties, end of life care or risk of MRPs postdischarge; 
potentially the MOAT could then be used as part of 
a suite of tools, permitting prioritisation of patients 
and appropriate allocation of workload among team 
members based on skills and expertise. The develop-
ment of these types of implementation strategies may 
also address patients’ views of safety; the medical view 
of patient safety often focusses on outcomes and avoid-
ance of harm,65 whereas patients tend to focus on what 
makes them ‘feel safe’, including processes of care, and 
interpersonal dynamics with care providers.66 67 The 
MOAT inherently fits a medical view of safety, with 
attention on ‘risk reduction’; incorporation of the 
MOAT into a holistic system offering tailored input to 
patients may therefore help provide a sense of safety 
for all patients.
strengths and limitations
To the best of our knowledge, the MOAT is the first 
evidence-based clinical prioritisation tool to identify 
inpatients most in need of pharmacists’ input (in terms 
of their risk of moderate or severe preventable MRPs).
Strengths of this research include adherence to the 
PROGRESS28 29 and TRIPOD recommendations,30 
at all stages of MOAT development. Other strengths 
include use of two study sites with markedly different 
patient demographics to increase generalisability, 
involvement of healthcare professionals and patient/
public representatives in selection of the decision 
thresholds, creation of risk groups, use of decision 
curve analysis and development of an electronic 
decision aid to simplify use and indicate a course of 
action.38 42 The choice of predictors is also a potential 
strength of this research, as their perceived relevance 
and ease of use are crucial to the clinical credibility 
of prediction models.68 We chose predictors with data 
that are readily available in clinical practice (to avoid 
the need for additional measurements),68 and avoided 
the need for complex calculations or categorisation 
(to ensure ease of use).68 We also chose clear predictor 
definitions to ensure standardisation and reproduc-
ibility (to enhance generalisability and applicability of 
study results to practice).69
A limitation of the study is possible underestima-
tion of the prevalence of MRPs due to pharmacists 
missing MRPs or not documenting them (as the MRP 
identification assessment exercise may suggest). This 
highlights the need for robust external validation of 
the MOAT, including the possible need for updating 
or recalibration.42 Another limitation was the inability 
to include predictors that are not routinely measured/
recorded in clinical practice, have low prevalence or 
had potential measurement error, due to the potential 
for inaccurate results.31 70 71 While this may be appro-
priate,38 data on excluded predictors will need to be 
shared with MOAT users to inform implementation. 
The observational nature of the study is another 
potential limitation, as data collection was not carried 
out under strict trial conditions, although this did 
permit the MOAT to reflect clinical practice in terms 
of MRP identification. Finally, the presence of a small 
amount of missing predictor data, and subsequent use 
of multiple imputation may be a limitation, although 
as data appeared to be ‘missing at random’, multiple 
imputation was less likely to introduce selection bias 
than complete-case analysis,42 72 in addition to being 
statistically more efficient.73
Implications for future research
External validation will be required to assess the 
MOAT’s accuracy and generalisability in a new group 
of patients.29 Following this, impact and implemen-
tation studies will be required to establish whether 
the MOAT has advantages over current practice, is 
compatible with (and can easily be incorporated into) 
practice, has the potential to change pharmacists’ 
behaviour, has a positive impact on patient outcomes 
and is cost effective.50
Further research may also be warranted into the use 
of risk categories. Organisations may differ in work-
force capacity and/or aversion to risk, resulting in a 
need to develop flexible thresholds, tailored either to 
organisational need or fluctuating staffing levels.
Another potential future development for the 
MOAT includes integration into automated systems 
such as electronic health records systems. This could 
result in the ability to perform accurate, automated 
risk assessments in ‘real-time’, which would further 
support implementation into clinical environments. It 
may also be possible to assess the transportability of 
the MOAT to determine its ability to produce accu-
rate predictions among people drawn from different 
but plausibly related populations,74 such as surgical 
patients, or patients in care homes.
conclusIon
We have developed and internally validated a prog-
nostic model to permit targeting of hospital patients 
most in need of pharmacists’ input based on their risk 
of moderate or severe preventable MRPs. Extensive 
external validation, involving prospective validation 
in a new cohort, will be required to further assess 
accuracy and generalisability before routine use can be 
recommended. Further research will also be required 
in terms of impact and implementation studies to 
assess the extent to which use of the MOAT may affect 
decision-making, improve efficiency or improve health 
outcomes.
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